NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
NRC HEALTH
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$20.47+0.32 (+1.59%)
Close on Oct 19, 2026
- Market cap
- $450.52M
- P/E (TTM)
- 0.4
- Dividend yield
- 2.54%
NRC HEALTH revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $147.42M | $148.58M | $148.72M | $148.47M | $149.40M | $150.78M | $150.29M | $149.71M | $144.99M | 100.0% | -1.3% |
| Canada | $0 | $0 | $0 | $0 | $203.00K | $793.00K | $1.43M | $2.09M | $2.97M | 0.0% | -100.0% |
From the segment and revenue-disaggregation notes of Nrc Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.